Dassault Systèmes makes $5.8bn health data deal

Software company Dassault Systèmes has targeted the life sciences sector with the $5.8 billion acquisition of Medidata Solutions, a US-firm firm focused on clinical trials.

In an announcement made yesterday, June 12, Dassault said that the Medidata acquisition, which is expected to be completed in the last quarter of 2019, would strengthen its position in the life sciences industry.

Bernard Charlès, vice chairman and CEO of Dassault, said: “Medidata’s recent expansion into real-world evidence and analytics coupled with the power of modelling and simulation demonstrates how the virtual world will catalyse the next generation of patient-inclusive therapeutics.”

Medidata offers a cloud-based platform allowing clients to build their own clinical trials and perform medical research.

The platform is comprised of more than 17,000 clinical trials and a clinical data repository with more than 4.8 million patients.

Medidata’s clients include some of the world’s biggest drugmakers and, according to Dassault, 13 of the top 15 drugs sold in 2018 relied on Medidata’s technology.

Glen de Vries, co-founder and president of Medidata, said: “Facilitating new therapeutic innovations to become the next standards of care has been our commitment since day one.”

De Vries added: “Ultimately, we will unlock enormous opportunities for our customers and patients, advancing life sciences in the age of precision medicine.”

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.